The company is betting that the alternative cytotoxic payload in its ADC can overcome resistance in patients who relapse on Enhertu.

Identifying Responders to Trastuzumab Therapy in Breast Cancer Anja Brügmann; Boe S Sorensen Disclosures Future Oncol. 2011;7 (6):767-773. 0 HER2 Measurements in Blood Fractions ...

Session ID: 2025-07-01:c3d96494478f7322ba15e67b Player Element ID: Vd5cd1b33_dfb7_4cb6_a47a_a289603d2ac9_6374240200112 ...

Results also showed an ORR of 85.1% with T-DXd plus pertuzumab vs. 78.6% with taxane therapy plus trastuzumab and pertuzumab, and a median duration of response of 39.2 months compared with 26.4 ...

Eribulin (Halaven) proved non-inferior to a taxane when added to trastuzumab-pertuzumab (HP) as first-line systemic treatment for patients with locally advanced/metastatic HER2+ breast cancer ...

Ann Oncol. 2024;35 (2):Abstract S378. Natsuhara KH, Blum K, LeVee AA, et al. Treatment rechallenge after trastuzumab-deruxtecan–related interstitial lung disease: a multi-institution cohort study.

And then for the patients who were taking trastuzumab deruxtecan, you could stop if you had toxicity, and in the pertuzumab arm, add trastuzumab as a maintenance approach.